Proteomic Profiling of Cerebrospinal Fluid by 8-Plex iTRAQ Reveals Potential Biomarker Candidates of Alzheimer’s Disease

Clinical Proteomics

M. Minkoff¹  B. Williamson¹  N. Guerreiro²  B. Gomez-Mancilla²  S. Guertin¹ 

[1] Applied Biosystems, Framingham, USAApplied Biosystems, Framingham, USAApplied Biosystems, Framingham, USA;BioMarker Development, Translational Sciences, Novartis, Basel, SwitzerlandBioMarker Development, Translational Sciences, Novartis, Basel, SwitzerlandBioMarker Development, Translational Sciences, Novartis, Basel, Switzerland

关键词: Liquid chromatography;    Neurodegeneration;    Proteome;    Neuroplasticity;    Inflammation;   

DOI  :  10.1007/s12014-009-9030-7

来源: Humana Press Inc

【 摘 要 】

Abstract

Introduction

Alzheimer’s disease (AD) poses specific challenges for drug development. It has a slow and variable clinical course, an insidious onset, and symptom expression is only observed when a significant proportion of neurons are already lost.

Discussion

Determinants of clinical course, such as molecular biomarkers, are urgently needed for early detection and diagnosis, or for prognosis and monitoring disease-modifying therapies in stratified patient populations. Due to its proximity to the brain and clinical availability, cerebrospinal fluid (CSF) is likely to have the highest yield of biomarker potential for neurodegenerative diseases. In this study, we examined the feasibility of using of an 8-plex isobaric tagging approach, coupled to two-dimensional liquid chromatography and tandem mass spectrometry using the matrix-assisted laser desorption/ionization time-of-flight/time-of-flight platform, for the discovery of potential biomarker candidates in CSF. Comparative analysis identified a number of statistically significant differences in the level of proteins when comparing AD to nondemented controls. Although the study is statistically underpowered to represent the disease population, the regulation of proteins with involvement in processes such as neuronal loss, synaptic dysfunction, neuroinflammation, and tissue degeneration and remodeling reflects the ability of our method in providing biologically meaningful CSF biomarkers as candidates for larger scale biomarker verification and validation studies.

【 授权许可】

Unknown